HOB BIOTECH(SH:688656) Zheng Quan Zhi Xing·2025-04-01 09:18Group 1 - The core viewpoint of the report is to summarize the sponsorship and regulatory compliance of Jiangsu Haobio Pharmaceutical Co., Ltd. during its initial public offering (IPO) on the Sci-Tech Innovation Board [1] - The issuer, Jiangsu Haobio Pharmaceutical Co., Ltd., has a registered capital of 63.058328 million yuan and was listed on January 13, 2021 [1] - The sponsor, Huatai United Securities Co., Ltd., conducted due diligence and prepared application documents in accordance with relevant laws and regulations [1][3] Group 2 - During the continuous supervision period, the sponsor conducted on-site inspections to check the use of raised funds, project progress, and corporate governance [3][4] - The sponsor identified non-operating fund occupation by related parties and conducted a special on-site inspection, requiring the company to strengthen internal training and governance [3][10] - The sponsor issued 26 verification opinions on the issuer's use of raised funds and related transactions, with no disapproval opinions issued [6][13] Group 3 - The issuer established a special account for raised funds and signed a tripartite supervision agreement with the sponsor and relevant banks [4] - The issuer's actual controller was involved in non-operating fund occupation, leading to internal penalties and a requirement to return the occupied funds [8][11] - The issuer's compliance with information disclosure requirements was affirmed, with no undisclosed matters identified [12][13] Group 4 - The report indicates that the issuer strictly followed regulations regarding the use of raised funds and fulfilled information disclosure obligations accurately [13] - The sponsor will continue to oversee the use of funds for the "New In Vitro Diagnostic Reagent R&D Center Project" until all funds are utilized [13]